1303 related articles for article (PubMed ID: 12826021)
1. Association between inflammatory mediators and the fibrinolysis system in infectious pleural effusions.
Alemán C; Alegre J; Monasterio J; Segura RM; Armadans L; Anglés A; Varela E; Ruiz E; Fernández de Sevilla T
Clin Sci (Lond); 2003 Nov; 105(5):601-7. PubMed ID: 12826021
[TBL] [Abstract][Full Text] [Related]
2. Cytokines and fibrinolytic enzymes in tuberculous and parapneumonic effusions.
Lin FC; Chen YC; Chen FJ; Chang SC
Clin Immunol; 2005 Aug; 116(2):166-73. PubMed ID: 15897010
[TBL] [Abstract][Full Text] [Related]
3. Metalloproteinases and tissue inhibitors of metalloproteinases in exudative pleural effusions.
Iglesias D; Alegre J; Alemán C; Ruíz E; Soriano T; Armadans LI; Segura RM; Anglés A; Monasterio J; de Sevilla TF
Eur Respir J; 2005 Jan; 25(1):104-9. PubMed ID: 15640330
[TBL] [Abstract][Full Text] [Related]
4. Proinflammatory cytokines, transforming growth factor-beta1, and fibrinolytic enzymes in loculated and free-flowing pleural exudates.
Chung CL; Chen CH; Sheu JR; Chen YC; Chang SC
Chest; 2005 Aug; 128(2):690-7. PubMed ID: 16100155
[TBL] [Abstract][Full Text] [Related]
5. Fibrinolytic and inflammatory processes in pleural effusions.
Philip-Joët F; Alessi MC; Philip-Joët C; Aillaud M; Barriere JR; Arnaud A; Juhan-Vague I
Eur Respir J; 1995 Aug; 8(8):1352-6. PubMed ID: 7489803
[TBL] [Abstract][Full Text] [Related]
6. Acute phase markers for the differentiation of infectious and malignant pleural effusions.
Kiropoulos TS; Kostikas K; Oikonomidi S; Tsilioni I; Nikoulis D; Germenis A; Gourgoulianis KI
Respir Med; 2007 May; 101(5):910-8. PubMed ID: 17270413
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of ferritin, interleukin-6, interleukin-8 and tumor necrosis factor alpha in the differentiation of exudates and transudates in pleural effusions.
Alexandrakis MG; Coulocheri SA; Bouros D; Eliopoulos GD
Anticancer Res; 1999; 19(4C):3607-12. PubMed ID: 10629659
[TBL] [Abstract][Full Text] [Related]
8. Proinflammatory cytokines and fibrinolytic enzymes in tuberculous and malignant pleural effusions.
Hua CC; Chang LC; Chen YC; Chang SC
Chest; 1999 Nov; 116(5):1292-6. PubMed ID: 10559090
[TBL] [Abstract][Full Text] [Related]
9. Vasoactive mediators (VEGF and TNF-alpha) in patients with malignant and tuberculous pleural effusions.
Hamed EA; El-Noweihi AM; Mohamed AZ; Mahmoud A
Respirology; 2004 Mar; 9(1):81-6. PubMed ID: 14982607
[TBL] [Abstract][Full Text] [Related]
10. Analysis of Cytokine Levers in Pleural Effusions of Tuberculous Pleurisy and Tuberculous Empyema.
Yang L; Hu YJ; Li FG; Chang XJ; Zhang TH; Wang ZT
Mediators Inflamm; 2016; 2016():3068103. PubMed ID: 27034588
[TBL] [Abstract][Full Text] [Related]
11. Intra-pleural fibrinolytic therapy versus placebo, or a different fibrinolytic agent, in the treatment of adult parapneumonic effusions and empyema.
Altmann ES; Crossingham I; Wilson S; Davies HR
Cochrane Database Syst Rev; 2019 Oct; 2019(10):. PubMed ID: 31684683
[TBL] [Abstract][Full Text] [Related]
12. IL-8 in pleural effusion.
Ceyhan BB; Ozgün S; Celikel T; Yalçin M; Koç M
Respir Med; 1996 Apr; 90(4):215-21. PubMed ID: 8736655
[TBL] [Abstract][Full Text] [Related]
13. Thrombin-antithrombin III complex, proinflammatory cytokines, and fibrinolytic indices for assessing the severity of inflammation in pleural effusions.
Lee MH; Nahm CH; Choi JW
Ann Clin Lab Sci; 2010; 40(4):342-7. PubMed ID: 20947808
[TBL] [Abstract][Full Text] [Related]
14. Vascular and fibrinolytic effects of intra-arterial tumour necrosis factor-alpha in patients with coronary heart disease.
Robinson SD; Dawson P; Ludlam CA; Boon NA; Newby DE
Clin Sci (Lond); 2006 Mar; 110(3):353-60. PubMed ID: 16309383
[TBL] [Abstract][Full Text] [Related]
15. Depression of tissue-type plasminogen activator and enhancement of urokinase-type plasminogen activator as an expression of local inflammation.
Brommer EJ; Dooijewaard G; Dijkmans BA; Breedveld FC
Thromb Haemost; 1992 Aug; 68(2):180-4. PubMed ID: 1412164
[TBL] [Abstract][Full Text] [Related]
16. Repeated thoracenteses affect proinflammatory cytokines, vascular endothelial growth factor, and fibrinolytic activity in pleural transudates.
Chung CL; Yeh CY; Sheu JR; Chen YC; Chang SC
Am J Med Sci; 2007 Dec; 334(6):452-7. PubMed ID: 18091367
[TBL] [Abstract][Full Text] [Related]
17. Pathways of fibrin turnover of human pleural mesothelial cells in vitro.
Idell S; Zwieb C; Kumar A; Koenig KB; Johnson AR
Am J Respir Cell Mol Biol; 1992 Oct; 7(4):414-26. PubMed ID: 1389210
[TBL] [Abstract][Full Text] [Related]
18. Hyaluronic acid levels are increased in complicated parapneumonic pleural effusions.
Zaga T; Makris D; Tsilioni I; Kiropoulos T; Oikonomidi S; Damianos A; Gourgoulianis KI
Monaldi Arch Chest Dis; 2011 Sep; 75(3):167-71. PubMed ID: 22428219
[TBL] [Abstract][Full Text] [Related]
19. Abnormalities of pathways of fibrin turnover in the human pleural space.
Idell S; Girard W; Koenig KB; McLarty J; Fair DS
Am Rev Respir Dis; 1991 Jul; 144(1):187-94. PubMed ID: 2064128
[TBL] [Abstract][Full Text] [Related]
20. Interleukin-8 is a major neutrophil chemotactic factor in pleural liquid of patients with empyema.
Broaddus VC; Hébert CA; Vitangcol RV; Hoeffel JM; Bernstein MS; Boylan AM
Am Rev Respir Dis; 1992 Oct; 146(4):825-30. PubMed ID: 1416405
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
